Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
54 results about "Colonic mucosa" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Antibiotic-free piglet creep feed
The invention provides an antibiotic-free piglet creep feed. The antibiotic-free piglet creep feed is prepared from the following raw materials in parts by weight: 45-50 parts of bulked corns, 8-13 parts of bulked soybeans, 13-17 parts of soybean meal, 1-2.5 parts of plasma protein powder, 2-4 parts of colonic mucosa protein powder, 1-4 parts of emulsified fat powder, 1-4 parts of soybean oil, 5-10 parts of whey powder, 2-5 parts of steam fish meal, 2-5 parts of glucose, 0.2-0.4 part of an acidifying agent, 0.1-0.3 part of montmorillonite, 1.2-1.5 parts of calcium hydrophosphate, 0.7-1.0 part of mountain meal, 0.2-0.5 part of table salt, 0.15-0.3 part of lysine, 0.1-0.2 part of methionine, 0.1-0.3 part of compound vitamins, 0.1-0.3 part of compound microelements, 0.05-0.15 part of an enzyme preparation and 0.05-0.15 part of a micro-ecological preparation. The antibiotic-free piglet creep feed is used for piglets that are 0-6 weeks old and piglets that are weaned for two weeks. By virtue of the antibiotic-free piglet creep feed, the feed intake of the piglets can be improved and the growth is promoted; and the diarrhea rate and weaning stress of the piglets are reduced and the utilization of antibiotics is reduced.
Owner:HENAN UNITED INVE FEEDSTUFF
Lactobacillus rhamnosus with effect of relieving colitis and application of lactobacillus rhamnosus
The invention provides lactobacillus rhamnosus with effect of relieving colitis and application of the lactobacillus rhamnosus. The strain is Lactobacillus rhamnosus NCU2217, and has been deposited atthe China General Microbiological Culture Collection Center (CGMCC for short) in April 9, 2018 at the address of Microbiology Research Institute of China Science Academy, No. 3, Courtyard 1, Beichenxi Road, Chaoyang Region, Beijing City with the accession number of CGMCC NO15573. By the lactobacillus rhamnosus and foods prepared from the same, the body weight of a mouse suffering from colitis canrecover fast and is increased, effects of inhibiting oxidative stress injury, reducing proinflammatory factors and increasing level of the proinflammatory factors are achieved, the level of short chain fatty acid in colonic fecal is increased remarkably, and meanwhile, injury of colonic mucosa can further be repaired.
Owner:NANCHANG UNIV
Traditional Chinese medicinal enema for treating chronic colitis
ActiveCN102727622AEnhance immune functionPromote local blood circulationDigestive systemPlant ingredientsToxic materialLicorice roots
The invention discloses a traditional Chinese medicinal enema for treating chronic colitis. According to the traditional Chinese medicinal science, the pathogenesis of chronic colitis is mainly due to syndromes of dampness-heat due to spleen deficiency and qi depression to blood stasis, especially develops in colonic mucosa and submucosa inflammation and ulcer changes, and is characterized by stomachache, diarrhea, mucous bloody stool and tenesmus in clinic. Therefore, traditional Chinese medicines, which have effects of clearing heat, drying damp, diminishing swelling, promoting granulation,removing pattogenic heat from the blood and toxic material from the body, relieving diarrhea, diminishing inflammation, resolving tetany and relieving pain, including traditional Chinese medicinal Swamp Mahogany Leaf, champion dutchmanspipe root, mongolian oak bark, Scutellaria baicalensis, cortex fraxini, Cape jasmine, Rhizoma Atractylodis Macrocephalae, licorice root, Codonopsis pilosula, cortex albiziae, fruits of Litsea rubescens, cortex cinnamomi and hurricane lamp, are selected to be made into the enema. Through clinical tests of our public health centre, the total effective rate of theenema reaches 96.3% and it is obviously better than a control group. In addition, patients have no adverse reaction after taking the medicine. Therefore, the medicine is worth of clinical popularization and application.
Owner:南通东湖国际商务服务有限公司
Bifidobacterium longum subsp. Longum capable of preventing and relieving colitis symptoms and application thereof
ActiveCN114164134AEasily damagedEasy to changeBacteriaDigestive systemBiotechnologyUlcerative colitis
The invention provides bifidobacterium longum subsp. Longum KLDS K5 capable of preventing and relieving symptoms of colitis, and belongs to the technical field of microorganisms. The invention further provides a preparation method of the bifidobacterium longum subsp. Longum KLDS K5. Experiments show that the bifidobacterium longum provided by the invention can tolerate the human gastrointestinal environment, relieve weight loss in the ulcerative colitis disease period, improve colonic mucosa injury and reduce MPO activity, and inhibit oxidation-related factors through iNOS and COX-2 signal pathways so as to relieve inflammatory bowel diseases; nF-kappa B p65 nuclear transfer is inhibited through a TLR4 / MyD88 / NF-kappa B signal channel, the expression quantity of proinflammatory factors TNF-alpha, IL-1beta, IL-6 and IL-10 in colon is reduced, the transcriptional level of colon tight connection related proteins Claudin-1, ZO-1 and Occludin and mucoprotein MUC2 is up-regulated, the intestinal flora change after DSS induction can be improved in the genus level, and the richness and diversity of the intestinal flora are improved.
Owner:NORTHEAST AGRICULTURAL UNIVERSITY
Lactobacillus fermentum capable of regulating intestinal tract Claudin-1 and application of lactobacillus fermentum
ActiveCN111560325AEnhanced barrier functionRepair damageMilk preparationBacteriaBiotechnologyMicroorganism
The invention discloses lactobacillus fermentum capable of regulating intestinal tract Claudin-1 and application of the lactobacillus fermentum, and belongs to the technical field of microorganisms. According to the lactobacillus fermentum CCFM1058 provided by the invention, the barrier function of intestinal mucosa can be effectively improved; compared with a colitis group, the lactobacillus fermentum CCFM1058 has the advantages that the expression level of the Claudin-1 protein gene is increased by nearly two times, and the colonic mucosal lesion is repaired. The level of lactobacillus fermentum CCFM1058 for improving the Claudin-1 is obviously better than that of a lactobacillus fermentum strain CECT5716 of a model strain. Therefore, the lactobacillus fermentum CCFM1058 with the function of regulating the Claudin-1 to protect the intestinal mucosa barrier has a wide application prospect in the fields of foods and microecological preparations.
Owner:JIANGNAN UNIV
Application of lactobacillus rhamnosus in preparation of food or medicine for preventing and/or treating ulcerative colitis
PendingCN114259056AImprove inflammatory lesionsImprove lesionPowder deliveryBacteriaBiotechnologyLactobacillus rhamnosus
The invention relates to application of lactobacillus rhamnosus to preparation of food or medicine for preventing and / or treating ulcerative colitis. The lactobacillus rhamnosus with the effect of relieving the ulcerative colitis is named as lactobacillus rhamnosus LRa05 strain, the preservation unit is China General Microbiological Culture Collection Center, the preservation time is July 20, 2020, the preservation number is CGMCC No.1. 12734, and the address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The lactobacillus rhamnosus LRa05 strain can be used for remarkably relieving the ulcerative colitis and remarkably improving the colonic mucosa inflammation lesion, and the lactobacillus rhamnosus LRa05 strain has a good prospect when being used for preparing the food or the medicine for preventing and / or treating the ulcerative colitis or the colonic mucosa inflammation.
Owner:JIANGSU WECARE BIOTECHNOLOGY CO LTD
Application of human derived HSF2 as specific diagnosis molecular marker of ulcerative colitis
InactiveCN103983687AHigh expressionMicrobiological testing/measurementMaterial analysis by electric/magnetic meansUlcerative colitisProteomic Profile
The invention relates to an application of human derived HSF2 as the specific diagnosis molecular marker of ulcerative colitis, and belongs to the technical field of biomedicine. The technical scheme comprises three parts: (1) detecting differential proteins in serums of UC patients and healthy volunteers through a proteomics two-dimensional gel electrophoresis technology and a mass spectrum technology; (2) detecting the HSF2 expression level in colonic mucosa of UC patients in different degrees through an immunohistochemical method; (3) detecting the HSF2 expression level in colonic mucosa of UC patients in different degrees through a real-time quantitative PCR technology and a western blotting technology. 40 UC patient serums and 40 healthy volunteer serums have been compared by the method mentioned above, and the results show that the expression of HSF2 in the UC patient serums prominently increases. Moreover, an immunohistochemical method, a real-time quantitative PCR technology and a western blotting technology are adopted to detect the HSF2 expression in the colonic mucosa of UC patients, and the results show that the HSF2 expression increases as the UC disease goes worse. Thus, the HSF2 can be used as a molecular marker to specifically diagnosing ulcerative colitis.
Owner:缪应雷
Specific antibody fragments for the human carcinoembryonic antigen (cea)
InactiveCN1649901AImprove performanceRadioactive preparation carriersImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody fragmentsIn vivo
The invention relates to mono- and bivalent (diabody) single-chain Fv-type (scFv) antibody fragments which are obtained using recombinant DNA techniques from the carcinoembryonic anti-antigen (CEA) monoclonal antibody (McA) CB / ior-CEA.1. The aforementioned McA has a high affinity for the CEA and is used in the diagnosis and monitoring of colorectal tumours in humans. As with the original McA, diabody and monovalent scFv fragments exhibit high affinities for the human CEA and recognise an epitope that is dependent on carbohydrate conservation. The diabody and monovalent scFv fragments have affinity constants for the CEA of (5.0 + / - 0.4) x 10<9> L mol<-1> and (2.8 + / - 0.3) x 10<10> L mol<-1> respectively. The two aforementioned fragments do not display cross-reactivity with normal human tissues and cells, except for the normal colonic mucosa where the CEA is occasionally present. Said fragments can be produced through expression in recombinant micro-organisms from the cloning of nucleic acid sequences that code for variable regions obtained from the hybridoma that is produced by the CB / ior-CEA.1 McA. As with the original McA, the diabody and the monovalent scFv have a capacity for the in vivo identification in rats of human CEA-producing cells which grow forming tumours. The monovalent scFv and diabody do not posses Fc domains and the molecular sizes of said monovalent scFv and diabody are 5 and 2.5 times, respectively, less than the rat McA. As a result, the aforementioned monovalent scFv and diabody can better penetrate tissues in vivo and are less immunogenic in humans.
Owner:CENT DE ING GENETICA & BIOTECNOLOGIA
Dendrobium officinale composition as well as preparation method and application thereof
PendingCN114404525AGood control effectIncrease abundanceDigestive systemNatural extract food ingredientsUlcerative colitisGoblet cell
The invention discloses a dendrobium officinale composition and a preparation method and application thereof.The dendrobium officinale composition is prepared from, by weight, 10-50 parts of dendrobium officinale and 5-30 parts of radix asparagi, the medicine components are mixed and smashed, a certain amount of water is added, the medicine components are soaked for a period of time and subjected to reflux extraction, an extracting solution is filtered, filtrate is subjected to vacuum concentration, and a traditional Chinese medicine composition extract is obtained. The composition disclosed by the invention has a relatively good prevention and treatment effect on ulcerative colitis, and can be used for remarkably reducing the disease activity score (DAI score) of a mouse with ulcerative colitis, increasing the colon length, improving the histological lesions such as colonic mucosa injury, inflammatory cell infiltration, goblet cell and mucus reduction and the like, and preventing and treating the ulcerative colitis. One of the ways for preventing and treating ulcerative colitis is to increase the abundance of UCG-007 bacteria in intestinal flora. The traditional Chinese medicine composition has the characteristics of simple formula and exact curative effect, and has better effect, lower cost and good market development and application prospects compared with single use of dendrobium officinale.
Owner:ZHEJIANG UNIV OF TECH
Recombinant plasmid, DNA vaccine, preparation method and application thereof
InactiveCN108893488AReduce damageGood treatment effectDigestive systemVertebrate antigen ingredientsRegulatory T cellPhosphorylation
The invention discloses a recombinant plasmid for specifically treating IBD, a DNA vaccine, a preparation method and an application thereof. In an experimental process of the invention, the injury degree of colonic mucosa of an IBD model rat of a treatment group injected with the DNA vaccine is obviously reduced and the score of activity index of enteritidis diseases is lower than that of a modelgroup, but the proinflammatory factors TNF-alpha and IL-6 of intestinal tracts of the model group are increased and T cells of CD4+CD25+Foxp3+ are less than those of pVAX1-TNFAIP3 treatment group. Meanwhile, phosphorylation level of the treatment group associated protein is obviously lower than that of the model group, so that pVAX1-TNFAIP3 is capable of inhibiting inflammation by inhibiting the activation of related inflammation signal channels; besides, the increasing of Foxp3 protein in colon shows that pVAX1-TNFAIP3 is capable of inhibiting inflammation by increasing regulatory T cells; the above results prove that pVAX1-TNFAIP3 recombinant plasmid and the prepared DNA vaccine have excellent therapeutic effects on inflammatory bowel diseases.
Owner:刘志强 +1
Application of modified nano iron oxide in preparation of medicine for preventing and/or treating inflammatory bowel disease
ActiveCN114028423AGood for weight lossImprove colonic bleedingHeavy metal active ingredientsDigestive systemIntestinal tract diseasesBowels diseases
The invention provides an application of modified nano iron oxide in preparation of a medicine for preventing and / or treating inflammatory bowel diseases. The modified nano iron oxide is gamma-Fe2O3 nano particles, positive electricity modified gamma-Fe2O3 nano particles, negative electricity modified gamma-Fe2O3 nano particles or polymer modified gamma-Fe2O3 nano particles. Different modifications are carried out on the nano iron oxide, so that the surfaces of the iron oxide nanoparticles have different charges and potential differences, the purpose of adsorbing different inflammatory proteins in intestinal tracts is achieved, the nano iron oxide adsorbing the inflammatory proteins is discharged out of a body, and the purpose of improving or relieving intestinal diseases is achieved. Experimental results show that the nano iron oxide with different modifications can significantly improve weight loss, disease index increase, colon bleeding, colon shortening, colonic mucosa hyperplasia and colitis response in a dextran sodium sulfate induced inflammatory bowel disease mouse model, so that the inflammatory bowel disease is treated.
Owner:THE GBA NAT INST FOR NANOTECHNOLOGY INNOVATION
Simple detection reagent for Warburg effect of human cells as well as preparation method and application of simple detection reagent
ActiveCN107132218AIncreased sensitivityStrong specificityMaterial analysis by observing effect on chemical indicatorVulvaOxygen
In order to solve the problems that PET-CT operating cost is high, severe radiation hazards are caused on human bodies and a reagent capable of simply and conveniently screening and detecting early cancerous cells does not exist, the invention provides a reagent capable of rapidly and accurately performing simple detection on a Warburg effect of human cells as well as a preparation method and application of the reagent. The simple detection reagent is composed of a reagent A, a reagent B, a reagent C and a reagent D. The human cell collection parts comprise colonic mucosa, skin, vulva and mouth mucosa. The reagent disclosed by the invention is capable of detecting free heme and reactive oxygen intensity of cells in cast-off cell samples, and the detected cells do not have any Warburg effect.
Owner:山东天倪生物技术有限公司
Bacteroides vulgatus capable of protecting intestinal permeability and application thereof
The invention discloses a strain of bacteroides vulgatus capable of protecting intestinal permeability and application thereof, and belongs to the technical field of microorganisms. The bacteroides vulgatus CCFM1152 provided by the invention has been preserved in the Guangdong Microbial Culture Collection Centre on November 9, 2020, and the preservation number is GDMCC No.61279. The bacteroides vulgatus CCFM1152 provided by the invention can effectively prevent weight loss and shortened colon length induced by DSS, reduce intestinal permeability and repair colonic mucosa injury. Therefore, the bacteroides vulgatus CCFM1152 has a wide application prospect in the aspect of preparing food and microecological preparations for protecting the intestinal permeability.
Owner:JIANGNAN UNIV
Application of shogfeelerica online A in preparation of drug for preventing and treating colitis
ActiveCN111467327APrevent edemaReduce Colon AtrophyAntipyreticDigestive systemIntestinal atrophyPharmaceutical drug
The invention discloses application of shogfeelerica online A in preparation of a drug for preventing and treating colitis. Researches in the invention show that the shogfeelerica online A is capableof improving clinical symptoms such as loose stools and bloody stools caused by the colitis, effectively reducing colon contraction, thinning colons, enhancing an intestinal tract barrier function andinhibiting edema of colonic mucosae and has no obvious side effect, so that the shogfeelerica online A has remarkable effects on prevention and treatment of the colitis and can be applied to the prevention and treatment of the colitis. The invention provides novel application of the shogfeelerica online A and also provides a new treatment drug and treatment way for the treatment of the colitis.
Owner:GUANGZHOU UNIVERSITY OF CHINESE MEDICINE
Tinidazol colon target biology adhesive tablet and preparation method thereof
InactiveCN101422444AMucoadhesiveIncrease concentrationAntibacterial agentsOrganic active ingredientsTinidazoleMedicine
The invention relates to the technical field of medicament preparation and discloses the composition of a tinidazole colon-targeted bioadhesive tablet. The tinidazole colon-targeted bioadhesive tablet comprises a skeleton tablet core which contains tinidazole, an adhesive accessory and an accessory used for dilution as well as a coat layer which contains polyacrylic resin, an accessory used for plastication, an accessory used for lubricating and a menstruum. The weight percentages (100 tablets) of each component are as follows: the skeleton tablet core contains 10 to 25g of tinidazole, 12 to 20g of the adhesive accessory, 0 to 2g of the accessory used for dilution as well as 0.1g of the accessory used for lubricating; and the coat layer contains 12.0 to 30.0g of the polyacrylic resin, 1.2 to 3.0g of the accessory used for plastication, 2.0 to 4.0g of the accessory used for lubricating and 200 to 500ml of the menstruum. The composition of the tinidazole colon-targeted bioadhesive tablet prolongs the staying time of the tinidazole in the colon, enhances the full contact and absorption between the medicament and the surface of a colonic mucosa, improves the local medicament concentration and reduces the medication use time.
Owner:SHENYANG PHARMA UNIVERSITY
Pharmaceutical composition for treating ulcerative colitis
InactiveCN106860453ADigestive systemHeterocyclic compound active ingredientsHalogenUlcerative colitis
The present invention relates to a pharmaceutical composition for treating ulcerative colitis, which comprises a compound of the following formula or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier: Wherein R1 is independently selected from: alkyl, alkoxy or halogen. The medicine of the invention has a certain degree of relieving effect on colonic mucosa edema, erosion and ulcer, thereby protecting colonic mucosa and achieving the purpose of treating ulcerative colitis.
Owner:杨燕
Method for separating crypts from colonic mucosa tissues and inducing generation of colonic organoids
PendingCN114134102AHigh densityPrecision medicineCell dissociation methodsGastrointestinal cellsColonic epitheliumLamina epithelialis
The invention relates to the field of stem cell organoid research, and discloses a method for separating crypts from colonic mucosa tissues and inducing to generate colonic organoid. Compared with the prior art, the method has the following advantages and effects that the elastin is degraded through Dispase, the connection between the colon epithelium and the intrinsic layer is loosened on the premise that cells are intact, the three micromolecules of Thiazovivin (TZV), SB431542 and CHIR99021 are added into the OGM culture medium to improve the organoid induction success rate, and the method has the advantages that the method is simple and convenient to operate, and the cost is low. The human colon-like organs can be reliably obtained with relatively low cost and relatively high efficiency; meanwhile, the method has the advantages that the method does not depend on a high-skill epithelial layer stripping technology; more primary colonic progenitor cells are obtained; the induction success rate of the primary culture medium on the colon-like organs is improved; and popularization and application are facilitated.
Owner:中诺(杭州)基因科技有限责任公司
Application of hyperin to treatment of ulcerative colitis
The invention discloses application of hyperin to treatment of ulcerative colitis. Through adoption of the hyperin, the MPO activity in colonic tissues can be obviously lowered, the degree of neutrophil infiltration can be reduced, and inflammation can be relieved; the ulcer area of colonic mucosa can be obviously reduced; colonic congestion and edema as well as intestinal wall adhesion can be relieved.
Owner:THE THIRD AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIV OF PLA
Application of zingerenone a in the preparation of drugs for preventing and treating colitis
ActiveCN111467327BPrevent edemaReduce Colon AtrophyAntipyreticDigestive systemIntestinal atrophySide effect
The invention discloses the application of zingerenone A in the preparation of drugs for preventing and treating colitis. The research of the present invention shows that zingerenone A can significantly improve clinical symptoms such as loose stools and bloody stools caused by colitis, effectively reduce colon atrophy, reduce colon thickness, enhance intestinal barrier function, and inhibit colonic mucosal edema without obvious side effects. Zingerenone A has a significant preventive effect on colitis and can be used in the prevention and treatment of colitis. The invention not only provides a new application of zingerenone A, but also provides a new therapeutic drug and a therapeutic approach for the treatment of colitis.
Owner:GUANGZHOU UNIVERSITY OF CHINESE MEDICINE
Promotion of healing of intestinal mucosa using proline, serine and threonine
InactiveCN107105751APromote healingReduce or prevent inflammationOrganic active ingredientsMilk preparationColonic epitheliumMedicine
Methods and compositions are provided that use proline, serine and threonine to promote healing of the intestinal mucosa. A therapeutically effective amount of proline, serine and threonine is administered to an individual in need thereof, for example a human or other mammal, such as an individual that has damaged intestinal mucosa. The methods and compositions can promote mucosal healing, restore gut barrier function, repair intestinal epithelial cells, promote protection of the colonic epithelium, and / or promote the replenishment of goblet cells in the intestinal and colonic mucosa.
Owner:SOC DES PROD NESTLE SA
Application of lactobacillus johnsonii in preventing and/or treating inflammatory bowel diseases
ActiveCN112121068ASymptoms improvedImprove symptoms, such as spleen hyperplasiaSalicyclic acid active ingredientsBacteriaBiotechnologyBowels diseases
The invention belongs to the field of biological medicines, and discloses an application of lactobacillus johnsonii in preparing a medicine for preventing and / or treating inflammatory bowel diseases,and an oral micro-ecological preparation for preventing and / or treating inflammatory bowel diseases. The micro-ecological preparation comprises lactobacillus johnsonii, such as a UMNLJ22 strain. The lactobacillus johnsonii can significantly improve spleen proliferation, colon shortening, colonic mucosa proliferation and colitis reaction in a Citrobacter rodentium-induced inflammatory bowel diseasemouse model, and it is found that the lactobacillus johnsonii can significantly relieve inflammatory bowel diseases of mice, so that the lactobacillus johnsonii is used for development and preparation of drugs for preventing and / or treating inflammatory bowel diseases.
Owner:CHINA AGRI UNIV
A non-antibiotic colitis repair preparation
ActiveCN110201026BGood antibacterial effectGood control effectOrganic active ingredientsDigestive systemBiotechnologyDisease
The present invention firstly provides a kind of composition, described composition comprises goose oil diglyceride and oregano oil; The mass ratio of described oregano oil and goose oil diglyceride is 1:8~12; The present invention The composition is suitable for preparing repair preparations for treating colitis. The present invention also provides a repairing preparation for colitis, which is prepared by using the above-mentioned composition. It is a specific preparation method, which is to form a mixture of oregano oil and goose oil diglyceride, and put it in a magnetic heating stirrer. Keep the temperature at 30-50° C., rotate at 300-800 rpm, and stir for 3-8 minutes to complete the preparation. Tests have shown that the synergy between oregano oil and goose oil diglyceride can repair the colonic mucosa, promote the digestion and absorption of intestinal nutrients, and promote the recovery of rat body weight, greatly increase its enteritis repair effect, and reduce the need for drugs during disease treatment. Use to make it repair while avoiding the problem of drug residue.
Owner:QINGDAO AGRI UNIV +1
A strain of Lactobacillus fermentum capable of regulating intestinal tight junction proteins and its application
ActiveCN111560325BEnhanced barrier functionRepair damageMilk preparationBacteriaBiotechnologyLactobacillus fermentum
Owner:JIANGNAN UNIV
Colitis repairing agent without anti-high cell affinity and application method
ActiveCN111617099ALower levelImprove physiological indicatorsDigestive systemUnknown materialsHigh cellUlcerative colitis
The invention provides a diglyceride preparation containing chitosan. The preparation comprises duck oil diglyceride and chitosan. The invention also provides an ulcerative colitis repairing agent prepared from the diglyceride preparation. A specific preparation method of the ulcerative colitis repairing agent comprises the step of fully mixing and stirring the duck oil diglyceride and the chitosan in a certain volume ratio. 4 mL / kg lactobacillus casei (activity unit: 108 CFU / ml) is fed in 2 h before feeding of the repairing agent. The composition can improve physiological indexes and intestinal flora structure of ulcerative colitis mice, reduce myeloperoxidase activity and reduce expression of inflammatory cytokines, can protect integrity of colonic mucosa and crypt glands, and can effectively repair ulcerative colitis. The ulcerative colitis repairing agent is a novel healthy ulcerative bowel disease repairing agent and clinical treatment scheme with great development value.
Owner:QINGDAO AGRI UNIV
Bifidobacterium bifidum for relieving constipation and application thereof
The invention provides bifidobacterium bifidum for relieving constipation and application of the bifidobacterium bifidum. The bifidobacterium bifidum for relieving constipation is named as a bifidobacterium bifidum BBi32 strain, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC NO.16923, the preservation date is December 10, 2018, and the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The bifidobacterium bifidum BBi32 provided by the invention can further increase the total content of short-chain fatty acids, so that the pH value of the intestinal environment is reduced, and the bifidobacterium bifidum BBi32 has the obvious characteristic of repairing colonic mucosal lesion, so that the purpose of relieving constipation is achieved.
Owner:JIANGSU WECARE BIOTECHNOLOGY CO LTD
Pharmaceutical composition for treating duodenal ulcer
InactiveCN104383316AReduce manufacturing costImprove securityAntipyreticAnalgesicsDuodenal ulcerUlcer healing
The invention discloses a pharmaceutical composition for treating duodenal ulcer. The pharmaceutical composition is prepared from the following Chinese herbal medicine raw materials and pharmaceutically acceptable auxiliary materials, wherein the Chinese herbal medicine raw materials comprise the following raw materials in parts by weight: 22-30 parts of cushaw tendril, 18-23 parts of shiny cinquefoil root, 18-25 parts of platycodon grandiflorum, 30-42 parts of chestnut shell, 30-42 parts of cucumber stem, 11-20 parts of golden cypress, 15-25 parts of glutinosae rice root, 6-10 parts of rose, 4-7 parts of impatiens balsamina and 11-20 parts of fructus viticis. The pharmaceutical composition disclosed by the invention used for promoting the restoration of colonic mucosa and quickly relieving a stomachache (the effect can reach 62.2% during the first week) by improving microcirculation; the healing rate of the duodenal ulcer after treatment of four weeks can reach 86.7%; and the pharmaceutical composition has a relatively good ulcer healing effect.
Owner:青岛申达高新技术开发有限公司
Application of glycine in prevention and/or treatment of inflammatory bowel disease
InactiveCN112402405AImproves symptoms associated with inflammatory bowel diseaseSymptoms improvedOrganic active ingredientsAntipyreticGlycineNutrition
The invention belongs to the field of biological medicines, and relates to application of glycine in preventing and / or treating inflammatory bowel diseases. Specifically, the invention finds that theglycine can significantly improve weight loss, disease index increase, spleen proliferation, colon shortening, colonic mucosa proliferation and colitis reaction in an inflammatory bowel disease mousemodel induced by Citrobacter rodentium, and further finds that the glycine can significantly alleviate inflammatory bowel disease of a mouse, and therefore, the glycine is used for development and preparation of drugs for preventing and / or treating the inflammatory bowel diseases. The application of the glycine provides a feasible thought for preventing and / or treating the inflammatory bowel diseases from the perspective of nutrition intervention.
Owner:CHINA AGRI UNIV
Traditional Chinese medicinal enema for treating chronic colitis
ActiveCN102727622BEnhance immune functionPromote local blood circulationDigestive systemPlant ingredientsLicorice rootsToxic material
Owner:南通东湖国际商务服务有限公司
Application of Lactobacillus johnsonii in the prevention and/or treatment of inflammatory bowel disease
ActiveCN112121068BSymptoms improvedImprove spleen hyperplasiaSalicyclic acid active ingredientsBacteriaMucosal hyperplasiaBowels diseases
The invention belongs to the field of biomedicine, and discloses the application of Lactobacillus johnsonii in the preparation of medicaments for preventing and / or treating inflammatory bowel disease, and a method for preventing and / or treating inflammatory bowel disease of oral probiotics comprising Lactobacillus johnsonii strains such as UMNLJ22. In the present invention, Lactobacillus johnsonii can significantly improve spleen hyperplasia, colon shortening, colonic mucosal hyperplasia and colon inflammatory response in the inflammatory bowel disease mouse model induced by Citrobacter rodentium, and it is found that Lactobacillus johnsonii can significantly Alleviate inflammatory bowel disease in mice, so as to be used for the development and preparation of medicaments for preventing and / or treating inflammatory bowel disease.
Owner:CHINA AGRI UNIV
Temperature-sensitive gel for repairing colonic mucosa
ActiveCN112773887AImprove stabilityDilution resistantOrganic active ingredientsPeptide/protein ingredientsUlcerative colitisPolyphenol
The invention belongs to the field of repairing pharmaceutical preparations and particularly relates to temperature-sensitive gel for repairing colonic mucosa. The temperature-sensitive gel is prepared from the following raw material components: a cell growth factor, epsilon-polylysine or salt thereof, a temperature-sensitive material, first polyphenol and second polyphenol, wherein the cell growth factor and the first polyphenol form a polyphenol-cell growth factor nano-composite; the epsilon-polylysine or the salt thereof, the temperature-sensitive material and the second polyphenol form a temperature-sensitive gel matrix; and the polyphenol-cell growth factor nano-composite is encapsulated in the temperature-sensitive gel matrix. The temperature-sensitive gel provided by the invention has dilution resistance, mucosa adhesion and antibacterial capability and also can be used for improving the stability of the cell growth factor; and after the temperature-sensitive gel is poured and administrated, the cell factor can be slowly released and the healing of ulcer mucosa is promoted, so that ulcerative colitis can be efficiently treated. The temperature-sensitive gel has the advantages of simple preparation method and good repeatability and large-scale production is easy to realize.
Owner:WENZHOU MEDICAL UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com